Off-label Drug Use
What is off-label drug use?
In the United States new drugs are tested in clinical trials (research studies) before they are approved for use in the general public. The clinical trials are done to prove that the drug:- Works to treat a certain medical condition
- Works the way it is expected to
- Is safe when used as directed
The drug label gives information about the drug, including the approved doses and how it's to be given to treat the medical condition for which it was approved. When a drug is used in a way that is different from that described in the FDA-approved drug label, it is said to be an "off-label" use. This can mean that the drug is:
- Used for a different disease or medical condition
- Given in a different way (such as by a different route)
- Given in a different dose than in the approved label
Off-label is also called "non-approved" or "unapproved" use of a drug.
Is off-label drug use legal?
The off-label use of FDA-approved drugs is not regulated, but it is legal in the United States and many other countries. An exception to this is the use of some controlled substances, such as opioids (pain medicines like morphine and fentanyl). These drugs cannot legally be prescribed in the United States except for approved purposes.While it is legal for doctors to use drugs off label, it is not legal for drug companies to market their drugs for off-label uses. This has been a hot news topic recently, as drug companies have been fined because they promoted drugs for uses not approved by the FDA. Off-label marketing is very different from off-label use.
Why are drugs used off-label?
Older, generic medicines are the ones most often used off label. New uses for these drugs may have been found and there is often medical evidence to support the new use. But the makers of the drugs have not put them through the formal, lengthy, and often costly studies required by the FDA to officially approve the drug for new uses.Off-label drug use is common in cancer treatment. There are many reasons for this:
- Some cancer drugs are found to work against many different kinds of tumors.
- Chemotherapy treatments often use combinations of drugs. These combinations might include one or more drugs not approved for that disease. Also, drug combinations change over time as doctors study different ones to find out which work best.
- Cancer treatment is always changing and improving.
- Oncologists and their patients are often faced with problems that have few approved treatment options.
- Oncologists and their patients may be more willing to try off-label drugs than other medical specialties.
What problems are caused by off-label drug use?
Reimbursement
The biggest problem is getting insurance plans to pay for off-label drug use (reimbursement). Many insurance companies will not pay for an expensive drug that is used in a way that is not listed in the approved drug label. They do this on the grounds that its use is "experimental" or "investigational."In cancer treatment, these issues have been largely addressed through 1993 federal legislation that requires insurance to cover medically appropriate cancer therapies. This law includes off-label uses if the treatment has been tested in careful research studies and written up in well-respected drug reference books or medical journals. In 2008, Medicare rules were changed to cover more off-label uses of cancer treatment drugs.
Still, the health insurance coverage laws and regulations are complex. If your doctor is thinking about off-label drug use, you and your doctor should carefully check your health plan's coverage. If coverage is denied the first time, it may help for the doctor to send the insurer copies of peer-reviewed journal articles or other respected sources that support the off-label use.
Legal risk
Another problem is that off-label drug use often does not reflect "standard of care" treatment. This leads to possible concern about the legal risk of prescribing off-label should a patient have an unwanted or bad outcome from the treatment.Lack of regulation and information
The FDA does not regulate the practice of medicine. In general, once the FDA approves a drug, licensed doctors can use it for any purpose they consider medically appropriate. Off-label use can vary greatly from one doctor to another. It depends on the doctor's preferences, knowledge, and past patient experiences.One of the biggest problems related to widespread off-label use is the lack of information about how to best use the drug beyond what was approved. One of the most reliable and easy-to-find sources of information available to health professionals, caregivers, and patients is the drug label. But the label can only contain the information that has been approved by the FDA, and it does not mention off-label uses.
The medical literature reports clinical trials, including those that are not part of the FDA approval process. This is the main source of off-label use information, although treatment guidelines may also offer options that include off-label use. Treatment guidelines are based on information from medical literature, including clinical trials, and recommend standard ways to treat certain diseases.
Lack of information on off-label drug use and outcomes may also put patients at a higher risk for medication errors, side effects, and unwanted drug reactions. It is important that the patient and doctor talk about the possible risks of using the drug and weigh them against the possible benefits.
How common is off-label drug use?
Little information is available on off-label prescribing in oncology in the US. Yet, a study done in 2008 found that 8 out of 10 cancer doctors surveyed had used drugs off-label. Off-label drug use is well-documented and very common in certain settings, such as pediatrics and HIV/AIDS care.Studies have reported that about half of the chemotherapy used is given for conditions not listed on the FDA-approved drug label. In fact, the National Cancer Institute (NCI) has stated, "Frequently the standard of care for a particular type or stage of cancer involves the off-label use of one or more drugs." Actual off-label use is likely much higher because chemotherapy is only one aspect of cancer treatment. Studies have yet to look at all the drugs used in cancer treatment, such as anti-nausea drugs and pain medicines.
What other ways are drugs used off label in cancer treatment?
One example of off-label drug use is tricyclic antidepressants to treat certain types of pain. This old class of antidepressant drugs is approved and labeled to be used for clinical depression. Today these drugs are seldom used for depression because safer drugs are now available to treat it. But doctors have found that the tricyclics often work very well in treating certain types of pain.Another example is lorazepam (Ativan®), an anti-anxiety drug often used as an anti-nausea drug in cancer treatment. In oncology, Ativan is most commonly given under the tongue (the sublingual route), which is also not listed on the drug label. In this case, it is being given for an off-label use and by an off-label route.
What questions should I ask my doctor about off-label drug use?
Here are some questions you may want to ask your doctor. Start by asking if all the drugs recommended for your cancer treatment are approved for the planned use. If any of the drugs are not, you can ask:- Is there evidence to support the off-label use of this drug to treat my type of cancer?
- Is this off-label drug likely to work better than an approved drug?
- What are the risks and benefits of off-label treatment with this drug?
- Will my health insurance cover off-label treatment with this drug?
- If my treatment involves a combination of drugs and one of the drugs is being used off label, will my health insurance cover it?
To learn more
More information from your American Cancer Society
We have selected some related information that may also be helpful to you. These materials are on our Web site (http://www.cancer.org/) or may be ordered from our toll-free number (1-800-227-2345).Clinical Trials: What You Need to Know
Health Insurance and Financial Assistance for the Cancer Patient (also available in Spanish)
Prescription Drug Assistance Programs (also available in Spanish)
Talking With Your Doctor (also available in Spanish)
Health Professionals Associated With Cancer Care
Understanding Chemotherapy: A Guide for Patients and Families (also available in Spanish)
Questions People Ask About Cancer (also available in Spanish)
National organizations and Web sites*
Along with the American Cancer Society, other sources of information and support include:National Cancer Institute
Toll-free number: 1-800-422-6237 (1-800-4-CANCER)
Web site: http://www.cancer.org/AboutUs/Redirect/index?h=http://www.cancer.gov&n=National%20Cancer%20institute
- Provides accurate, up-to-date information about cancer to patients, their families, and the general public, also has a free clinical trials matching service
Toll-free number: 1-888-463-6332
Web site: http://www.cancer.org/AboutUs/Redirect/index?h=http://www.fda.gov/cder&n=US%20Food%20and%20Drug%20Administration%20Center%20for%20Drug%20Evaluation%20and%20Research
- Offers information about approved drugs, but cannot discuss drugs under investigation unless the company making the drug has published material on that drug. Will provide contact information for drug companies if callers know the name of the company
*Inclusion on this list does not imply endorsement by the American Cancer Society.
No matter who you are, we can help. Contact us anytime, day or night, for cancer-related information and support. Call us at 1-800-227-2345 or visit http://www.cancer.org/. References
American Society of Clinical Oncology. Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications. J Clin Oncol. 2006;24:3206−3208.Fairman KA, Curtiss FR. Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010. JMCP. 2010;16(8):629−639.
Kocs D, Fendrick AM. Effect of Off-label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience. The American Journal of Managed Care. 2003;9:393−402.
Largent EA, Miller FG, Pearson SD. Going Off-label Without Venturing Off-Course: Evidence and Ethical Off-label Prescribing. Arch Intern Med. 2009;169:1745−1747.
Mortenson LE. The off-label debate: a threat to the future of cancer care. Cancer Invest. 1991;9:597−599.
National Cancer Institute. Understanding the Approval Process for New Cancer Treatments. Q&A: Off-Label Drugs. Accessed at www.cancer.gov/clinicaltrials/education/approval-process-for-cancer-drugs/page5 on March 10, 2011.
Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008;26(36):5994−6000.
Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer. 2004;12:302−305.
Thakkar S. Oncologists judge themselves the best judges of cancer treatments. J Natl Cancer Inst. 1997;89:1188−1189.
United States General Accounting Office. Off-label drugs, reimbursement policies constrain physicians in their choice of cancer therapies (report GAO/PEMD-91-14). September 1991. Washington DC. Accessed at http://archive.gao.gov/d18t9/144933.pdf on March 10, 2011.
No hay comentarios:
Publicar un comentario